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Abstract
We have recently shown that cardiolipin (CL) and its
metabolites move from mitochondria to other cellular
membranes during death receptor-mediated apoptosis. In this
study, we investigate the immunoreactivity to CL derivatives
occurring during endothelial apoptosis in patients with
antiphospholipid syndrome (APS) and systemic lupus
erythematosus (SLE). We compared the serum
immunoreactivity to CL with that of its derivatives
monolysocardiolipin (MCL), dilysocardiolipin (DCL), and
hydrocardiolipin (HCL) by means of both enzyme-linked
immunosorbent assay and thin-layer chromatography (TLC)
immunostaining. In addition, we investigated the composition of
phospholipid extracts from the plasma membrane of apoptotic
endothelial cells and the binding of patients' sera to the surface
of the same cells by using high-performance TLC and
immunofluorescence analysis. The average reactivity to MCL
was comparable with that of CL and significantly higher than
that for DCL and HCL in patients studied, both in the presence
or in the absence of beta2-glycoprotein I. Of relevance for the
pathogenic role of these autoantibodies, immunoglobulin G
from patients' sera showed an increased focal reactivity with the
plasma membrane of endothelial cells undergoing apoptosis.
Interestingly, the phospholipid analysis of these light membrane
fractions showed an accumulation of both CL and MCL. Our
results demonstrated that a critical number of acyl chains in CL
derivatives is important for the binding of antiphospholipid
antibodies and that MCL is an antigenic target with
immunoreactivity comparable with CL in APS and SLE. Our
finding also suggests a link between apoptotic perturbation of
CL metabolism and the production of these antibodies.
Introduction
Patients with antiphospholipid syndrome (APS) show high lev-
els of circulating antiphospholipid antibodies (aPLs) and are
prone to arterial and venous thrombosis, recurrent abortions,
and/or foetal loss [1-3]. aPLs are heterogeneous antibodies
binding to phospholipids, proteins, or phospholipid-protein
complexes. Historically, cardiolipin (CL) was used as an anti-
gen for aPL determination [4]. In 1990, different reports
described the requirement of beta2-glycoprotein I (β2-GPI) for
the binding of anticardiolipin antibodies (aCLs) in solid-phase
immunoassays [5-7]. Although β2-GPI represents the best tar-
get antigen in the pathogenesis of APS, other phospholipid-
aCL = anticardiolipin antibody; aMCL = antimonolysocardiolipin antibody; aPL = antiphospholipid antibody; APS = antiphospholipid syndrome; β2-
GPI = beta2-glycoprotein I; BSA = bovine serum albumin; CL = cardiolipin; COX-IV = subunit IV of cytochrome c oxidase; DCL = dilysocardiolipin; 
ELISA = enzyme-linked immunosorbent assay; ER = endoplasmic reticulum; FCS = foetal calf serum; HCL = hydrocardiolipin; HCV = hepatitis C 
virus; HPTLC = high-performance thin-layer chromatography; HUVEC = human umbilical vein endothelial cell; IgG = immunoglobulin G; LBPA = 
lyso(bis)phosphatidic acid; LPC = lysophosphatidylcholine; MCL = monolysocardiolipin; MS = mass spectrometry; PBS = phosphate-buffered saline; 
PBS-F = phosphate-buffered saline-foetal calf serum; PM = plasma membrane; SLE = systemic lupus erythematosus; TLC = thin-layer chromatog-
raphy; TNF-α = tumour necrosis factor-alpha; VDAC-1 = voltage-dependent anion channel-1.Arthritis Research & Therapy    Vol 8 No 6    Alessandri et al.
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binding proteins have been described as phospholipid cofac-
tors [8-12]. Moreover, it has been reported that in infectious
diseases aCL recognises CL in the absence of β2-GPI [13-
16].
CL is a unique anionic phospholipid composed of two phos-
phate groups and four fatty acid chains and represents the
most unsaturated (susceptible of oxidation) lipid of the body
[17,18]. In particular, the degree of unsaturation of the acyl
chains in CL influences the binding of β2-GPI to CL, whereas
(hydro)peroxidation of CL has been shown to be essential for
enhancing the binding of aPLs [19]. Although CL is predomi-
nantly associated with the inner mitochondrial membrane
(where CL synthase is located), its rapid re-modelling into the
highly unsaturated species that are most common in adult tis-
sues (for example, tetra-linoleyl-CL) occurs in other mem-
branes. CL re-modelling, in fact, involves relocation to the
outer mitochondrial membrane, as well as to extra-mitochon-
drial compartments [17,18], with rapid de-acylation into mono-
and di-lysocardiolipin (with three and two acyl chains, respec-
tively). These metabolites are transported to the endoplasmic
reticulum (ER) for efficient re-acylation into the mature forms of
CL found in mitochondria in a process that seems to be facili-
tated by lipid transfer proteins like Bid [20]. Consistent with
such a multi-organelle cycle of CL re-modelling, we have
recently shown that CL is exposed on the plasma membrane
(PM) of cells undergoing apoptosis induced by death recep-
tors like Fas and tumour necrosis factor-alpha (TNF-α)
[21,22]. This translocation onto the cell surface implies a leak-
age of CL (and/or of its metabolites) from the normal re-mod-
elling cycle [20], probably as a consequence of an apoptosis-
mediated increase of ER and secretory membranes. This leak
might well represent an in vivo trigger for the generation of
aCL [21,22]. Interestingly, mass spectroscopy analysis has
demonstrated an early degradation of mitochondrial CL into its
immediate metabolite, monolysocardiolipin (MCL), during Fas-
induced apoptosis [23]. This finding has been subsequently
confirmed in human pro-monocytic U937 cells [22].
The recent data have increased our attention on the role of CL
metabolites and, in general CL acylation, on the generation
and properties of aCL, a subject that has been analysed by a
limited number of studies so far [24,25]. In the present study,
we demonstrate that the number of acyl chains in CL deriva-
tives is important not only for the binding of β2-GPI, but also
for the generation of epitopes of 'pure' aCL for specific CL
metabolites like MCL. In addition, we show that CL and its key
derivative, MCL, re-locate to the PM of human umbilical vein
endothelial cells (HUVECs) undergoing apoptosis. We sug-
gest that aCL and antimonolysocardiolipin antibody (aMCL)
might derive from alteration in the metabolism of CL as a pos-
sible consequence of enhanced apoptosis.
Materials and methods
Patients
Twenty-eight immunoglobulin G (IgG) aCL-positive outpa-
tients were enrolled after clinical referral to the Division of
Rheumatology of the University of Rome 'La Sapienza.' All
patients were positive for medium-to-high levels of IgG aCL
according to our standard enzyme-linked immunosorbent
assay (ELISA) (β2-GPI-dependent) 89 GPL, range 40 to 120).
Eighteen patients had APS according to the Sapporo criteria
[3] primary (n = 6) or secondary (n = 12) to systemic lupus
erythematosus (SLE), and 10 patients had SLE fulfilling Amer-
ican College of Rheumatology criteria [26]. The clinical and
serological features of the patients are summarised in Table 1.
We enrolled 24 healthy subjects as controls (13 female and
11 male; mean age 34 years, range 22 to 52 years). Finally, to
establish whether aPL reactivity from patients with infections
was different than that from patients with APS and SLE, we
selected three sera from 37 hepatitis C virus (HCV) patients
previously deemed positive for IgG aCL by ELISA and thin-
layer chromatography (TLC) immunostaining [27]. None of the
healthy subjects or the selected HCV patients experienced
arterial or venous thrombosis or recurrent foetal loss. After
informed consent was obtained, each subject underwent
peripheral blood sample collection and the sera were then
stored at -20°C until assayed.
Materials
CL (bovine heart) was obtained from Sigma-Aldrich (St. Louis,
MO, USA). MCL, dilysocardiolipin (DCL), and hydrogenated
('reduced') CL (HCL) were obtained from Avanti Polar Lipids,
Inc. (Alabaster, AL, USA). TLC was performed as previously
described [28] to assess the purity of the phospholipid prep-
arations (data not shown). Human β2-GPI was obtained from
Chemicon International (Temecula, CA, USA).
In addition to human sera, the following antibodies were used:
rabbit polyclonal anti-human β2-GPI (Chemicon International),
mouse monoclonal anti-transferrin receptor (CD71; BD
Pharmingen, San Diego, CA, USA), goat polyclonal anti-volt-
age-dependent anion channel-1 (VDAC-1)/porin (N18; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and mouse
monoclonal anti-subunit IV of cytochrome c oxidase (COX-IV)
(Molecular Probes, now part of Invitrogen Corporation,
Carlsbad, CA, USA); alkaline phosphatase-conjugated sec-
ondary antibodies (goat anti-human and mouse anti-rabbit
IgG) were purchased from Sigma-Aldrich.
Human IgG fractions were first isolated with 33% ammonium
sulphate fractionation from plasma of patients with APS and
from healthy donors as previously described [21,22]. Protein
concentration was measured with the method of Lowry and
colleagues [29], and the purity of the IgG preparations was
confirmed by SDS-PAGE.Available online http://arthritis-research.com/content/8/6/R180
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ELISA for aPLs
Briefly, pure phospholipids (50 μg/ml) in ethanol were used to
coat microtitre plates by incubation at 4°C overnight. In this
way, oxidation of phospholipids occurs during the coating
process as previously reported [19]. After four washes with
phosphate-buffered saline (PBS), plates were blocked for 1
hour at room temperature with PBS containing 10% foetal calf
serum (PBS-F). After four washes with PBS-F, plates were
incubated for 90 minutes at room temperature with sera sam-
ples diluted at 1:50 or human IgG (100 μl of concentrated
solutions of 4.8 mg/ml) in PBS-F. Titration of aCL/aMCL-pos-
itive sera was performed by serial dilution (1:25 to 1:1,000) in
PBS-F by using measurements in triplicate. Moreover, a rabbit
polyclonal anti-β2-GPI was used to detect the levels of β2-GPI
bound to lipids. After four washes with PBS-F, the plates were
incubated for 90 minutes at room temperature with secondary
anti-human IgG and anti-rabbit IgG (Sigma-Aldrich) diluted to
1:1,000 in PBS-F; after multiple washes, immunoreactivity
was developed using the alkaline phosphatase substrate
(paranitrophenyl phosphate in ethanolamine). The enzyme
reaction was evaluated from the absorbance at 405 nm in a
plate reader. To account for the different molecular weights of
CL derivatives, we performed ELISA with lipids coated to the
plate at the same molarity. Finally, to perform β2-GPI-inde-
pendent ELISA, 1% bovine serum albumin (BSA) or 0.25%
gelatine was used in the blocking and washing steps. All
assays were performed at least in duplicate, and the non-spe-
cific binding was evaluated by subtracting the absorbance of
non-specific binding of each serum in wells without antigens.
Absorption test
To investigate the specificity of the assay, competitive inhibi-
tion tests were performed according to technique described
previously [30,31]. Briefly, serum samples (1:50 in PBS con-
taining 1% BSA) were pre-incubated for 60 minutes at 37°C
with increasing amounts of CL or its derivatives dried onto the
surface of glass tubes. Subsequently, the tubes were centri-
fuged (10,000 g for 30 minutes) and the supernatants were
tested for reactivity toward CL derivatives.
Immunostaining on TLC plates for aPLs
The immunostaining of TLC plates (Merck, Darmstadt, Ger-
many) was performed as described previously [28], using 2.5
μg of CL, MCL, DCL, and HCL. IgG fractions (2.4 mg/ml) from
Table 1
Demographic and clinical features of the patients studied
APS SLE
(n = 18) (n = 10)
Females/Males 15/3 9/1
Age in years
Mean (range) 38.4 (28–68) 36.9 (18–59)
Disease duration in months
Mean (range) 121 (1–322) 119 (12–300)
Vascular thrombosis
Venous thrombosis (percentage) 14/18 (77.7) 0
Arterial thrombosis (percentage) 8/18 (44.4) 0
Recurrent thrombosis (percentage) 4/14 (28.5) 0
Pregnancy morbidity
Normal foetus deaths (percentage) 0 0
Premature births (percentage) 1/18 (5.5) 0
Spontaneous abortions (percentage) 9/18 (50) 0
Serological features
aCL IgG (percentage) 18/18 (100) 10/10 (100)
aCL IgM (percentage) 11/18 (61) 5/10 (50)
Anti-β2-GPI IgG 18/18 (100) 10/10 (100)
Anti-β2-GPI IgM ND ND
Lupus anticoagulant activity (percentage)a 15/18 (83.3) 5/10 (50)
aLupus anticoagulant activity was deduced from recent clinical records. aCL, anticardiolipin antibody; APS, antiphospholipid syndrome; β2-GPI, 
beta2-glycoprotein I; IgG, immunoglobulin G; IgM, immunoglobulin M; ND, not done; SLE, systemic lupus erythematosus.Arthritis Research & Therapy    Vol 8 No 6    Alessandri et al.
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both APS sera (which had been deemed aCL-positive by
standard ELISA screening) and normal human sera were
diluted 1:100 or 1:1,000 in PBS containing 0.5% (wt/vol) gel-
atine. Parallel blots were processed without primary antibody
or without antigen as control for non-specific reactivity.
Western blotting
BSA, gelatine, and human β2-GPI were run on 12% SDS-
PAGE and electro-transferred to nitrocellulose membrane
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Membranes
were blocked with PBS containing 5% defatted dry milk and
then probed with rabbit polyclonal anti-β2-GPI antibodies.
Antibody binding was detected using alkaline phosphatase-
conjugated secondary antibodies and visualised with a kit con-
taining chromogenic alkaline phosphatase substrate (Bio-Rad
Laboratories, Inc.) according to manufacturer's instructions.
The reaction was stopped by washing in distilled water.
Indirect immunofluorescence of cells
Cellular indirect immunofluorescence was carried out to ana-
lyse CL expression on the PM of HUVECs, which were iso-
lated by collagenase perfusion from normal-term umbilical
cord veins as described previously [32]. Cells were cultured in
M-199 medium (Sigma-Aldrich) supplemented with 20% foe-
tal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin at 37°C in a humidified atmos-
phere of 5% CO2. HUVECs were grown to 60% to 70% con-
fluence, transferred at 5 × 106  cells per well on glass
coverslips, either untreated or treated with 20 ng/ml TNF-α
and 10 μg/ml cycloheximide for 16 hours [33,34], and fixed in
PBS containing 4% formaldehyde for 1 hour at 4°C. Apopto-
sis was evaluated by morphologic analysis and by propidium
iodide staining according to Nicoletti and colleagues [35].
After three washes with PBS, cells were incubated for 1 hour
at 4°C with purified human IgG from APS patients (aCL- and
aMCL-positive) in PBS containing 1% BSA. Alternatively, after
previous absorption with CL or MCL as reported above, cells
were incubated for 1 hour at 4°C with purified human IgG from
APS patients. Fluorescein isothiocyanate-conjugated anti-
human IgG (γ-chain specific; Sigma-Aldrich) were then added
and incubated at 4°C for 30 minutes. After a washing with
PBS, fluorescence was analysed with an Olympus U RFL
microscope (Olympus, Tokyo, Japan). In parallel experiments,
cells were directly stained before formaldehyde fixation. Alter-
natively, cells were processed for a second formaldehyde fixa-
tion immediately after the incubation with purified IgG and
before the addition of the secondary antibody. Neither fixation
procedure affected the staining on the cell surface [21].
Phospholipid analysis on light membrane fractions
Subcellular fractions were isolated from HUVECs as previ-
ously reported [22]. Briefly, control untreated cells or cells
treated with 20 ng/ml TNF-α and 10 μg/ml cycloheximide for
16 hours were rinsed with cold isolation buffer (0.25 M man-
nitol, 1 mM EDTA, 10 mM K-HEPES, 0.2% BSA, pH 7.4) con-
taining a cocktail of protease inhibitors (Sigma-Aldrich),
resuspended in 1 ml of the same buffer, and homogenised vig-
orously. After a brief centrifugation at 600 g in the cold isola-
tion buffer, pellet and supernatant were combined,
rehomogenised, and centrifuged at 800 g for 10 minutes at
4°C. The pellet was discarded and the supernatant was further
centrifuged at 10,000 g for 10 minutes at 4°C. The pellets
(P10) were washed three times with assay buffer (0.12 M
mannitol, 0.08 M KCl, 1 mM EDTA, 20 mM K-HEPES, pH 7.4,
containing a cocktail of protease inhibitors) and then resus-
pended in the same buffer. The supernatant was further cen-
trifuged at 100,000 g for 1 hour at 4°C to obtain the cytosolic
supernatant (S100) and the light membrane pellet (P100). The
latter was dissolved in assay buffer, normalised for protein
content by Bio-Rad protein assay (Bio-Rad Laboratories, Inc.),
split into two aliquots, and analysed for phospholipid compo-
sition by TLC and for the presence of mitochondrial and endo-
somal contaminants by Western blotting. Phospholipids were
extracted according to the technique described by Folch and
colleagues [36] and separated by TLC by using high-perform-
ance TLC (HPTLC) silica gel 60 (10 × 10) plates (Merck).
Chromatography was performed in chloroform/methanol/ace-
tic acid/water (100:75:7:4) (vol/vol/vol/vol). After exposure to
iodide vapours, the bands comigrating with the CL and MCL
standard were scraped, eluted from silica with chloroform/
methanol (2:1) (vol/vol), and dried under nitrogen. Phospholi-
pids were run using methanol/chloroform/NH3 (7:13:1) and
stained with copper acetate. Alternatively, light membranes
were diluted with assay buffer containing protease inhibitors
and adjusted to a final protein concentration of 0.5 to 1 mg/ml
with concentrated SDS sample buffer. Protein samples were
separated by SDS-PAGE and blotted in PBS containing
0.05% Tween-20 with the following antibodies to exclude the
presence of mitochondrial contaminants: mouse monoclonal
anti-transferrin receptor (CD71), goat polyclonal anti-VDAC-
1/porin, and mouse monoclonal anti-COX-IV. Blots were visu-
alised by chemiluminescence reaction by using the ECL West-
ern detection system (Amersham Biosciences, now part of GE
Healthcare, Little Chalfont, Buckinghamshire, UK). Protein
loading was evaluated by india ink staining [37].
Statistical analysis of data
Statistical analysis of data was carried out using Mann-Whit-
ney's  U  test for comparison of means between different
groups of subjects. Wilcoxon paired test was used to compare
differences between aCL derivative profiles in each group of
patients and controls. Correlation analysis was carried out by
the Spearman test. P less than 0.05 was considered statisti-
cally significant.
Results
Binding of aPLs to CL and its derivatives by ELISA
The levels of serum antibodies reacting with CL, MCL, DCL,
and HCL in patients and controls were quantified by ELISA,
and the overall data are shown in Figure 1. Similar results wereAvailable online http://arthritis-research.com/content/8/6/R180
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obtained when purified human IgG were used instead of sera
(data not shown). The average immunoreactivity to CL and
MCL was significantly higher than that for DCL and HCL, both
in APS (P < 0.0001) and SLE patients (P < 0.001) (Figure 1).
In addition, the same reactivity profile was observed when CL
derivatives were coated onto plates at the same molarity, even
if under these conditions the amount (weight) of coated lipids
may have been slightly different. All three patients with HCV
positive for aCL IgG were also positive for aMCL. Thus, our
results indicated that, at least in solid-phase immunoassays, a
key derivative of CL such as MCL represents a lipid easily rec-
ognised by sera autoantibodies. To study this novel observa-
tion in more detail, we performed titrations with representative
sera showing strong reactivity for both CL and MCL (Figure
2a). The concentration dependence of the antibody titre indi-
cated that binding to MCL saturated as efficiently as that to
CL, whereas reactivity toward both DCL and HCL remained
very low and did not saturate at all (Figure 2a). To further char-
acterise the IgG specificity of binding, three sera positive for
both aCL and aMCL were tested in ELISA after absorption
with increasing amounts of CL and its derivatives. As shown in
Figure 2b, pre-absorption with both CL and MCL significantly
decreased the binding of aCL to CL. Similar results were
observed when binding of aMCL to MCL was analysed after
absorption with CL and MCL (Figure 2c). In contrast, when
sera were pre-absorbed with either DCL or HCL, no significant
competition in the binding of both aCL and aMCL was
observed (Figure 2b,c). These findings suggest that CL and
MCL present identical epitopes, or at least overlapping
epitopes.
β2-GPI dependence of immunoreactivity to CL and its 
derivatives
All the aCL/aMCL-positive sera of patients with APS and SLE
were found to react also with β2-GPI as detected by standard
ELISA (data not shown). Conversely, none of the controls
(healthy subjects and patients with HCV) was positive for anti-
β2-GPI.
We observed that the isolated β2-GPI protein could bind to
MCL other than CL (Figure 3a). Intriguingly, the protein also
showed a significant binding to DCL, with an affinity that
appeared to be comparable with that for CL. So, although β2-
GPI attached itself to both MCL and CL, it equally reacted with
DCL in vitro (Figure 3a), whereas APS sera displayed only low
reactivity toward DCL (Figures 1 and 2). In this respect, it is
interesting to note that the reactivity of SLE and APS sera
toward other negatively charged lipids such as lyso(bis)phos-
phatidic acid (LBPA) [27,38] could be mediated by the rela-
tively non-specific interaction that serum proteins like β2-GPI
may have with chemically different phospholipids sharing a
negative charge.
Figure 1
Box-and-whisker plots of autoantibodies binding to cardiolipin (CL) and its derivatives Box-and-whisker plots of autoantibodies binding to cardiolipin (CL) and its derivatives. Median, quartiles, range, and possibly extreme values are 
shown. NHS indicates healthy donors. (a) anticardiolipin reactivity; (b) antimonolysocardiolipin reactivity; (c) antidilysocardiolipin reactivity; (d) anti-
hydrocardiolipin reactivity. The average immunoreactivities to CL and monolysocardiolipin were significantly higher than those for dilysocardiolipin 
and hydrocardiolipin, both in antiphospholipid syndrome (APS) (P < 0.0001) and systemic lupus erythematosus (SLE) patients (P < 0.001) (a, b). 
aCL, anticardiolipin antibody; aDCL, antidilysocardiolipin antibody; aHCL, antihydrocardiolipin antibody; aMCL, antimonolysocardiolipin antibody; 
OD, optical density.Arthritis Research & Therapy    Vol 8 No 6    Alessandri et al.
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To determine whether aCL/aMCL binds directly to lipids, we
performed ELISA in the absence of serum proteins (for exam-
ple, FCS) or in the presence of other proteins like BSA or gel-
atine. Clearly, patients' autoantibodies retained high reactivity
toward both CL and MCL in the absence of FCS and irrespec-
tive of the exogenous proteins used for blocking the plate
matrix (Figure 3b). To exclude the possibility that BSA or gel-
atine was contaminated with the serum protein β2-GPI that
Figure 2
Dilution and absorption tests Dilution and absorption tests. (a) Immunoglobulin G binding of 
selected sera positive for both anticardiolipin antibody (aCL) and anti-
monolysocardiolipin antibody (aMCL) was enhanced by increasing the 
concentration of cardiolipin (CL) derivatives coated on the enzyme-
linked immunosorbent assay (ELISA) plate wells. To further character-
ise the antigen specificity, three aCL/aMCL-positive sera were tested in 
ELISA after pre-absorption with increasing concentrations of CL deriva-
tives. Pre-absorption with CL and monolysocardiolipin (MCL) signifi-
cantly decreased the binding of aCL to CL (b) and of aMCL to MCL 
(c), respectively. No significant competitions were observed with dilys-
ocardiolipin (DCL) and hydrocardiolipin (HCL) pre-absorption concern-
ing the binding of both aCL and aMCL sera (b, c). Each data point 
represents the mean of triplicate determinations. OD, optical density.
Figure 3
Beta2-glycoprotein I (β2-GPI) dependence of immunoreactivity to cardi- olipin (CL) derivatives Beta2-glycoprotein I (β2-GPI) dependence of immunoreactivity to cardi-
olipin (CL) derivatives. (a) Binding of β2-GPI to CL and its derivatives. 
Intriguingly, β2-GPI showed significant binding to CL, monolysocardioli-
pin (MCL), and dilysocardiolipin (DCL), which was comparable with 
that for CL at the highest concentration tested. Each data point repre-
sents the mean of triplicate determinations. (b) Box-and-whisker plot of 
antimonolysocardiolipin antibody (aMCL) binding in six antiphospholi-
pid syndrome (APS) patients. Median, quartiles, range, and possibly 
extreme values are shown. The blocking and the washing steps were 
performed with foetal calf serum (FCS) (10%) in phosphate-buffered 
saline (PBS)-Tween-20 to provide the β2-GPI or with bovine serum 
albumin (BSA) (1%) or gelatine (0.5%) to avoid the presence of β2-
GPI, which is commonly associated with FCS. No significant difference 
of aMCL reactivity was observed with different blocking solutions. (c) 
Thin-layer chromatography (TLC) immunostaining analysis of: lane 1: 
normal serum, diluted 1:100 in PBS/0.5% gelatine; lane 2: control pos-
itive aCL serum, diluted 1:100 in PBS/0.5% gelatine; lane 3: APS 
serum positive for both aCL and aMCL, diluted 1:100 in PBS/0.5% 
gelatine; lane 4: APS serum positive for both aCL and aMCL, diluted 
1:1,000 in PBS/0.5% gelatine. No sera showed reactivity against DCL 
and hydrocardiolipin (HCL). The results in lanes 3 and 4 are represent-
ative of five different APS patients. OD, optical density; St, standard 
phospholipid visualisation of lipids (cardiolipin, hydrocardiolipin, mon-
olysocardiolipin, and dilysocardiolipin) by iodide vapours.Available online http://arthritis-research.com/content/8/6/R180
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avidly binds CL and its derivatives (Figure 3a), we performed
Western blot analysis with a specific anti-β2-GPI antibody. The
results did not show detectable levels of β2-GPI in the samples
of BSA or gelatine used in the experiments (data not shown).
In another approach, we tested the immunoreactivity of aCL/
aMCL-positive sera toward pure lipids separated by TLC in the
complete absence of exogenous proteins that might interfere
with the autoantibody reactivity with phospholipids. TLC
immunostaining of five representative aCL/aMCL-positive sera
showed strong reactivity to a combination of CL and MCL
(Figure 3c). No sera showed reactivity against DCL and HCL.
Next, we performed experiments to assess the possible contri-
bution of β2-GPI toward aCL and aMCL reactivity in TLC
immunostaining. Considering that β2-GPI is normally present
in concentrations of approximately 200 μg/ml in human sera,
we performed immunostaining on TLC with sera that had been
diluted to 1:1,000. With such a dilution, β2-GPI levels would
fall below the minimum requirement (>0.5 μg/ml) for allowing
binding of aCL to anionic phospholipids [39]. As previously
demonstrated [40,41], TLC immunostaining showed a reactiv-
ity with CL and MCL up to a dilution of 1:1,000 (Figure 3c,
lane 4), thereby excluding a major contribution of serum pro-
teins to the observed immunoreactions to CL derivatives.
Binding of aCL and aMCL to HUVECs undergoing 
apoptosis
To evaluate whether apoptosis may represent a possible trig-
ger for autoantibody production toward CL and MCL, human
IgG fractions from APS patients were used to analyse the dis-
tribution pattern of CL (and MCL also) on the surface of apop-
totic HUVECs. Reactivity showed specificity for CL and MCL,
given that no significant reactions were detected by TLC
immunostaining between IgG fractions and other phospholip-
ids such as phosphatidylserine, phosphatidylinositol, and
LBPA. No antinuclear reactivity of IgG fractions was observed
by standard indirect immunofluorescence on Hep2 cells. To
promote apoptosis, we used treatment with TNF-α plus
cycloheximide under conditions that were previously shown to
induce high levels of endothelial cell death [33,34]. Fluores-
cence microscopy analysis revealed that human IgG fractions
displayed a stronger binding to the surface of HUVECs under-
going apoptosis as compared with untreated cells (Figure
4a,b). The enhanced staining onto the PM appeared uneven,
indicating that the reactivity was concentrated in localised
areas on or near the cell surface. Most likely, these areas coin-
cided with PM patches where active membrane traffic and re-
modelling were most intense (for example, blebbing precur-
sors, which subsequently give rise to apoptotic bodies)
(Figure 4b). A virtual absence of immunolabelling was
observed across internal membranes, suggesting that intracel-
lular CL was somehow shielded from autoantibody reactivity.
Interestingly, a very low staining was observed after previous
absorption with CL or MCL in both untreated cells (Figure 4c
and 4d, respectively) or cells treated with TNF-α plus
cycloheximide (not shown). As a negative control, human IgG
from healthy subjects showed negligible surface staining of
HUVECs, either untreated or after TNF-α and cycloheximide
treatment (not shown).
To further investigate the above observations, we isolated light
membrane fractions containing PMs of apoptotic and
untreated HUVECs. Phospholipids were extracted and the
presence of CL and MCL was verified by HPTLC (Figure 4e).
Strong bands corresponding to CL and MCL were identified
only in the membrane fractions of apoptotic cells. The PM
enrichment of the light membrane fractions was confirmed by
Western blot analysis, which showed strong reactivity against
the membrane protein marker transferrin receptor, with the vir-
tual absence of mitochondrial (VDAC-1/porin and COX-IV)
contaminants (Figure 4f). Hence, the results obtained with
HUVECs undergoing apoptosis were similar to those reported
previously with U937 cells [21,22] and indicated that CL and
MCL become surface-exposed and much more accessible to
autoantibody recognition after induction of apoptosis.
Discussion
In this study, we report for the first time that sera from APS and
SLE patients display strong reactivity toward MCL, a key
metabolite of CL. MCL is the immediate product of CL degra-
dation, a process that has been shown to occur either in mito-
chondria (both membranes) as part of the re-modelling cycle
of the mature lipid or in lysosomes [20,42]. CL is among the
most resistant phospholipids toward phospholipase A2
hydrolysis in membranes of healthy cells. However, significant
levels of MCL exist in healthy tissues and increase after stimu-
lation of physiological apoptotic pathways such as Fas/FasL,
which are relevant to white blood cells and immunological
response [22,23]. In this context, our finding of autoantibodies
that cross-react with CL and MCL could provide a pathologi-
cally relevant link between the metabolic cycle and membrane
traffic of CL and apoptosis. Indeed, CL is known to undergo
degradation (including peroxidation) during many pathways of
cell death [42].
Recent findings have suggested that CL and its metabolites
may be transported by apoptosis regulator proteins like Bid,
especially after caspase cleavage [23,43]. On the other hand,
we recently demonstrated that CL becomes exposed onto the
PM of myelomonocytic cells undergoing apoptosis in vitro,
suggesting that intracellular traffic of CL may enhance CL
immunogenicity in vivo [21] as previously described for other
autoantigens [44]. Of relevance to this issue, Casciola-Rosen
and coworkers [45] have shown aCL binding to surface blebs
of apoptotic cells, which would be consistent with the
clustering of aCL immunostaining in focal surface regions that
we detected in apoptotic endothelial cells. This indicates that
cells undergoing apoptosis expose CL on their surface in seg-
regated membrane regions that could enhance the binding of
circulating autoantibodies. In this view, we consider that ourArthritis Research & Therapy    Vol 8 No 6    Alessandri et al.
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previous findings of CL reactivity on the cell surface of apop-
totic cells [21] could reflect a combined recognition of
exposed CL and MCL. Indeed, our original findings in the
present work suggest a prominent role of both CL and MCL in
Figure 4
Binding of aCL antibodies and aMCL to HUVECs undergoing apoptosis Binding of aCL antibodies and aMCL to HUVECs undergoing apoptosis. (a) Immunofluorescence of untreated HUVECs. The staining of cells with 
the human immunoglobulin G (IgG) fractions from antiphospholipid syndrome (APS) sera was followed by fluorescein isothiocyanate-conjugated 
secondary antibody. Cells showed a fairly low and disperse immunolabelling. (b) Immunofluorescence of apoptotic HUVECs. The staining appears 
uneven and focalised in regions over the plasma membrane. Immunofluorescence of untreated HUVECs after previous absorption with both (c) CL 
and (d) MCL. The staining of cells with the human IgG fractions from APS sera was very low. Images were collected at 512 × 512 pixels, and results 
are representative of three repeats. (e) Light membrane pellets from either apoptotic or non-apoptotic HUVECs were analysed for phospholipid 
composition by thin-layer chromatography. Strong bands corresponding to CL and MCL were identified only in the membrane fractions of apoptotic 
HUVECs. (f) Western blot analysis of protein samples from light membranes showed strong reactivity against the membrane protein marker transfer-
rin receptor (Tfr), with the virtual absence of mitochondrial (VDAC-1/porin and COX-IV) contaminants. CHX, cycloheximide; COX-IV, subunit IV of 
cytochrome c oxidase; St, standard phospholipid visualisation of lipids (cardiolipin, hydrocardiolipin, monolysocardiolipin, and dilysocardiolipin) by 
iodide vapours; TNF-α, tumour necrosis factor-alpha; VCAC-1, voltage-dependent anion channel-1.Available online http://arthritis-research.com/content/8/6/R180
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eliciting a pathological autoimmune reactivity in APS and
related conditions. Moreover, we demonstrated for the first
time the relocation of CL and MCL to the PM of apoptotic
HUVECs, which are largely involved in the pathogenesis of
APS. In contrast, in our extensive mass spectrometry (MS)
studies of membrane lipids and their changes after the induc-
tion of apoptosis, we detected very low levels of MS signature
ions for DCL species in the PM of apoptotic cells, suggesting
that in most cells DCL is present in trace amounts with respect
to CL and MCL, most likely reflecting a combination of rapid
re-modelling turnover in the ER and lysosomal degradation in
by-products of CL catabolism [22]. These findings might
explain the low DCL reactivity that we found in sera of both
APS and SLE patients.
Our data also demonstrate that the chemistry of the acyl
chains of CL is important not only for the binding to β2-GPI, but
also for the intrinsic immunogenicity of the CL molecule. We
also demonstrate here that the serum protein β2-GPI shows a
differential binding to CL derivatives (MCL > CL > DCL),
which, although similar, does not entirely match the reactivity
exhibited by SLE and APS sera. In fact, by using both ELISA
and TLC immunostaining, we found that sera can also bind
with high efficiency to MCL and CL in the absence of β2-GPI.
Thus, our data support the notion that aCL and anti-β2-GPI
represent two distinct populations of antibodies [40] with
overlapping but not coincident antigenic recognition. In this
respect, pathogenic human monoclonal antibodies that bind
phospholipids in the absence of β2-GPI have been described
[46,47]. Likewise, the binding of plasmatic β2-GPI to CL and
MCL on the cell surface after apoptotic stimuli is possible.
Thus, we cannot exclude the possibility that aPLs may also be
directed to this phospholipid-protein complex.
After an early report showing different reactivity of various CL
derivatives with Wassermann antibody [48], only a few inves-
tigations have been published on the role of the acyl chains of
CL in binding of aPLs [24,25,49-51]. Notably, Qamar and co-
workers [49] suggested a potential role of the fatty acyl chains
in the binding of autoantibodies to lysophosphatidyleth-
anolamine. Another study concluded that aPL binding as mon-
itored with an ELISA system depends on the fatty acid moiety
of phospholipids but is also influenced by the nature of their
polar head and phosphodiester groups [24]. Interestingly, the
authors of this work suggested that in vivo aPLs may bind to
intermediate ('transition') membrane phospholipids, which
could expose their fatty acid chains that contributed to anti-
body recognition. In accordance with recent insights into the
role of CL and its re-modelling in apoptosis [23,42,43], we
propose that both CL and MCL are the 'transition' membrane
lipids suggested earlier [24]. In agreement with this possibility,
Berger and colleagues [25] suggested that the number of acyl
chains in CL may represent a significant factor in the binding
of aPLs. However, they detected a significant decrease of
binding to MCL in 12 SLE aCL-positive sera [25]. The discrep-
ancy with our data may be due to the selection of patients
based on their high reactivity to CL or to the small number of
patients tested as well as to the different dilution of the sera
[25]. More recently, antibodies to lysophosphatidylcholine
(LPC) have been identified indicating that LPC may also con-
tribute to the antigenicity of oxidised low-density lipoproteins
[49,50]. Moreover, a strong correlation between antibodies
directed to LPC and CL was found [50]. It is noteworthy that
LPC is a by-product of CL re-modelling, PC being the predom-
inant acyl donor for MCL during re-modelling [18]. On the
other hand, it has also been suggested that CL, after oxidation,
could be hydrolysed by serum phospholipase, thus creating
molecular structures similar to either LPC or MCL [50]. Inter-
estingly, phospholipase A2 activity is enhanced in both
autoimmune and inflammatory diseases [51], as well as during
apoptosis [20]. Consistent with our study, it is thus possible
that CL hydrolysis of one fatty acid chain to yield MCL
enhances CL antigenicity. In addition, MCL has hybrid proper-
ties between a diacyl-lipid (bilayer-forming) and a lyso-lipid
(micelle-forming), which may physically facilitate autoantibody
reactivity. In contrast, there are fundamental physico-chemical
reasons why autoantibodies fail to bind to DCL because this
lipid has an unusually large and hydrophilic polar head with
respect to any other (di-acyl) phospholipid. DCL may have as
many as five free hydroxyl groups in its polar head, some of
which are likely to produce intramolecular hydrogen bonds
that would change the geometry and overall structure of the
lipid. Then, in the likely event of partial peroxidation of the acyl
chains, additional hydrogen bonds could be formed between
the polar head groups and the oxygenated fatty acids, produc-
ing large changes that alter the overall structure of the mole-
cule. Such changes will strongly modify the docking properties
and on/off constants of lipid binding to the cognate hydropho-
bic pockets in serum immunoglobulins (or other CL-interacting
proteins). In the case of APS serum proteins, their binding to
CL is critically determined by the conformation and chemistry
of the acyl chains, as demonstrated here by the lack of binding
to the hydrogenated CL analogue, which shows baseline lev-
els comparable with those of DCL. Whereas MCL could main-
tain the overall structural determinants that enable the
recognition of CL, the further loss of an acyl chain in DCL
destroys the binding affinity because of the large structural
alterations that distinguish this lipid from its related metabo-
lites and, overall, from most other di-acyl lipids.
Conclusion
In this study, we describe a high reactivity of APS and SLE
sera to MCL, the immediate degradation product of mitochon-
drial CL. We propose a model in which apoptosis or inflamma-
tory processes enhance the hydrolysis (and membrane traffic)
of CL into MCL, which can then escape the metabolic cycle of
lipid re-modelling. MCL can then become exposed to the cell
surface and consequently to the immune system, either
directly or through the interaction with a plasma protein such
as β2-GPI. Interestingly, these events may occur in vivo in cellsArthritis Research & Therapy    Vol 8 No 6    Alessandri et al.
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directly involved in the pathogenesis of APS, such as mono-
cytic and endothelial cells, as demonstrated by us in in vitro
experiments. Hence, a deranged process of CL metabolism
could stimulate autoantibody reactivity by the synergistic bind-
ing to MCL.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CA carried out the ELISA experiments and the experiments on
the endothelial cell line, participated in the design of the study
and in the analysis of data, and drafted the manuscript. MS
participated in the design of the study and in the analysis of
data and helped to draft the manuscript. MB carried out the
ELISA experiments and the experiments on endothelial cells
and contributed to the interpretation of data. PC carried out
the ELISA experiments and participated in the analysis of data.
AL and TG carried out the immunoassay and participated in
the analysis of data and in the revision of the manuscript. VM
carried out the experiments of TLC immunostaining and
immunofluorescence.  FC performed the statistical analysis,
the clinical associations, and the revision of the study. ME
participated in the design of the study and in the revision of the
manuscript. GV conceived of the study, participated in its
design and coordination, and drafted the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by Fondazione Umberto di Mario.
References
1. Hughes GR: The anticardiolipin syndrome.  Clin Exp Rheumatol
1985, 3:285-286.
2. Hughes GR, Harris NN, Gharavi AE: The anticardiolipin
syndrome.  J Rheumatol 1986, 13:486-489.
3. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette
JC, Brey R, Derksen R, Harris EN, Hughes GR, et al.: International
consensus statement on preliminary classification criteria for
definite antiphospholipid syndrome: report of an international
workshop.  Arthritis Rheum 1999, 42:1309-1311.
4. Pangborn MC: A new serologically active phospholipid from
beef heart.  Proc Soc Exp Biol Med 1941, 48:484-486.
5. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van
Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM: Anticardioli-
pin antibodies (ACA) directed not to cardiolipin but to a
plasma protein cofactor.  Lancet 1990, 335:1544-1547.
6. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Anti-phos-
pholipid antibodies are directed against a complex antigen
that includes a lipid-binding inhibitor of coagulation: beta 2-
glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci USA
1990, 87:4120-4124.
7. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T: Anticar-
diolipin cofactor(s) and differential diagnosis of autoimmune
disease.  Lancet 1990, 336:177-178.
8. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG:
Development of an ELISA for autoantibodies to prothrombin
showing their prevalence in patients with lupus anticoagulant.
Thromb Haemost 1995, 74:1120-1125.
9. Sorice M, Griggi T, Circella A, Lenti L, Arcieri P, Domenico di Nucci
G, Mariani G: Protein S antibodies in acquired protein S
deficiencies.  Blood 1994, 83:2383-2384.
10. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN,
de Groot PG: Antiphospholipid antibodies directed against a
combination of phospholipids with prothrombin, protein C or
protein S: an explanation for their pathogenic mechanism?
Blood 1993, 81:2618-2625.
11. Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y: Clinical
significance of anti-annexin V antibodies in patients with sys-
temic lupus erythematosus.  Am J Hematol 1997, 54:209-213.
12. Giles IP, Isenberg DA, Latchman DS, Rahman A: How do
antiphospholipid antibodies bind beta2-glycoprotein I?  Arthri-
tis Rheum 2003, 48:2111-2121.
13. Sorice M, Pittoni V, Griggi T, Losardo A, Leri O, Magno MS, Misasi
R, Valesini G: Specificity of anti-phospholipid antibodies in
infectious mononucleosis: a role for anti-cofactor protein
antibodies.  Clin Exp Immunol 2000, 120:301-306.
14. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida
T, Yasuda T, Koike T: Heterogeneity of anticardiolipin antibod-
ies defined by the anticardiolipin cofactor.  J Immunol 1992,
148:3885-3891.
15. Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO: Reactiv-
ity to beta 2 glycoprotein I clearly differentiates anticardiolipin
antibodies from antiphospholipid syndrome and syphilis.
Thromb Haemost 1996, 75:717-720.
16. Ordi-Ros J, Villarreal J, Monegal F, Sauleda S, Esteban I, Vilardell
M: Anticardiolipin antibodies in patients with chronic hepatitis
C virus infection: characterization in relation to antiphospholi-
pid syndrome.  Clin Diagn Lab Immunol 2000, 7:241-244.
17. Hatch GM: Cardiolipin: biosynthesis, remodeling and traffick-
ing in the heart and mammalian cells (Review).  Int J Mol Med
1998, 1:33-41.
18. Schlame M, Rustow B: Lysocardiolipin formation and reacyla-
tion in isolated rat liver mitochondria.  Biochem J 1990,
272:589-595.
19. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Ter-
keltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL:
Antiphospholipid antibodies are directed against epitopes of
oxidized phospholipids. Recognition of cardiolipin by mono-
clonal antibodies to epitopes of oxidized low density
lipoprotein.  J Clin Invest 1996, 98:815-825.
20. Esposti DM: Lipids, cardiolipin and apoptosis: a greasy licence
to kill.  Cell Death Differ 2002, 9:234-236.
21. Sorice M, Circella A, Misasi R, Pittoni V, Garofalo T, Cirelli A, Pavan
A, Pontieri GM, Valesini G: Cardiolipin on the surface of apop-
totic cells as a possible trigger for antiphospholipids
antibodies.  Clin Exp Immunol 2000, 122:277-284.
22. Sorice M, Circella A, Cristea IM, Garofalo T, Di Renzo L, Alessandri
C, Valesini G, Esposti MD: Cardiolipin and its metabolites move
from mitochondria to other cellular membranes during death
receptor-mediated apoptosis.  Cell Death Differ 2004,
11:1133-1145.
23. Esposti MD, Cristea IM, Gaskell SJ, Nakao Y, Dive C: Proapop-
totic Bid binds to monolysocardiolipin, a new molecular con-
nection between mitochondrial membranes and cell death.
Cell Death Differ 2003, 10:1300-1309.
24. Levy RA, Gharavi AE, Sammaritano LR, Habina L, Lockshin MD:
Fatty acid chain is a critical epitope for antiphospholipid
antibody.  J Clin Immunol 1990, 10:141-145.
25. Berger A, German JB, Gershwin ME: Implications of modifying
cardiolipin acyl composition by diet. 1. Cardiolipin acyl chain is
an important determinant in the binding to antiphospholipid
antibodies in SLE sera.  J Autoimmun 1992, 5:229-241.
26. Hochberg MC: Updating the American College of Rheumatol-
ogy revised criteria for the classification of systemic lupus
erythematosus.  Arthritis Rheum 1997, 40:1725.
27. Alessandri C, Bombardieri M, Di Prospero L, Conigliaro P, Conti F,
Labbadia G, Misasi R, Sorice M, Valesini G: Anti-lysobisphos-
phatidic acid antibodies in patients with antiphospholipid syn-
drome and systemic lupus erythematosus.  Clin Exp Immunol
2005, 140:173-180.
28. Sorice M, Griggi T, Circella A, Garofalo T, d'Agostino F, Pittoni V,
Potieri GM, Valesini G: Detection of antiphospholipid antibod-
ies by immunostaining on thin layer chromatography plates.  J
Immunol Methods 1994, 173:49-54.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein meas-
urement with Folin phenol reagent.  J Biol Chem 1951,
193:265-275.
30. Horkko S, Olee T, Mo L, Branch DW, Woods VL Jr, Palinski W,
Chen PP, Witztum JL: Anticardiolipin antibodies from patients
with the antiphospholipid antibody syndrome recognizeAvailable online http://arthritis-research.com/content/8/6/R180
Page 11 of 11
(page number not for citation purposes)
epitopes in both beta(2)-glycoprotein 1 and oxidized low-den-
sity lipoprotein.  Circulation 2001, 103:941-946.
31. Horkko S, Miller E, Branch DW, Palinski W, Witztum JL: The
epitopes for some antiphospholipid antibodies are adducts of
oxidized phospholipid and beta2 glycoprotein 1 (and other
proteins).  Proc Natl Acad Sci USA 1997, 94:10356-10361.
32. Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato
A, Khamashta M, Hughes GR, Zanussi C, Balestrieri G, et al.:
Relationship between anti-cardiolipin and anti-endothelial cell
antibodies in systemic lupus erythematosus.  Clin Exp
Immunol 1988, 74:247-253.
33. Xu J, Yeh CH, Chen S, He L, Sensi SL, Canzoniero LM, Choi DW,
Hsu CY: Involvement of de novo ceramide biosynthesis in
tumor necrosis factor-alpha/cycloheximide-induced cerebral
endothelial cell death.  J Biol Chem 1998, 273:16521-16526.
34. Margutti P, Sorice M, Conti F, Delunardo F, Racaniello M, Alessan-
dri C, Siracusano A, Riganò R, Profumo E, Valesini G, Ortona E:
Screening of an endothelial cDNA library identifies the C-ter-
minal region of Nedd5 as a novel autoantigen in systemic
lupus erythematosus with psychiatric manifestations.  Arthritis
Res Ther 2005, 7:R896-R903.
35. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A
rapid and simple method for measuring thymocyte apoptosis
by propidium iodide staining and flow cytometry.  J Immunol
Methods 1991, 139:271-279.
36. Folch J, Lees M, Sloane-Stanley GH: A simple method for the
isolation and purification of total lipids from animal tissues.  J
Biol Chem 1957, 226:497-509.
37. Hancock K, Tsang VC: India ink staining of proteins on nitrocel-
lulose paper.  Anal Biochem 1983, 133:157-162.
38. Galve-de Rochemonteix B, Kobayashi T, Rosnoblet C, Lindsay M,
Parton RG, Reber G, de Maistre E, Wahl D, Kruithof EK, Gruen-
berg J, de Moerloose P: Interaction of anti-phospholipid anti-
bodies with late endosomes of human endothelial cells.
Arterioscler Thromb Vasc Biol 2000, 20:563-574.
39. Wang SX, Cai G, Sui S: Intrinsic fluorescence study of the
interaction of human apolipoprotein H with phospholipid
vesicles.  Biochemistry 1999, 38:9477-9484.
40. Sorice M, Circella A, Griggi T, Garofalo T, Nicodemo G, Pittoni V,
Pontieri GM, Lenti L, Valesini G: Anticardiolipin and anti-beta 2-
GPI are two distinct populations of autoantibodies.  Thromb
Haemost 1996, 75:303-308.
41. Sorice M, Pittoni V, Circella A, Misasi R, Conti F, Longo A, Pontieri
GM, Valesini G: Anti-prothrombin but not "pure" anti-cardioli-
pin antibodies are associated with the clinical features of the
antiphospholipid antibody syndrome.  Thromb Haemost 1998,
80:713-715.
42. McMillin JB, Dowhan W: Cardiolipin and apoptosis.  Biochim
Biophys Acta 2002, 1585:97-107.
43. Esposti MD, Erler JT, Hickman JA, Dive C: Bid, a widely
expressed proapoptotic protein of the Bcl-2 family, displays
lipid transfer activity.  Mol Cell Biol 2001, 21:7268-7276.
44. Utz PJ, Gensler TJ, Anderson P: Death, autoantigen modifica-
tions, and tolerance.  Arthritis Res 2000, 2:101-114.
45. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in
systemic lupus erythematosus are clustered in two popula-
tions of surface structures on apoptotic keratinocytes.  J Exp
Med 1994, 179:1317-1330.
46. Ikematsu W, Luan FL, La Rosa L, Beltrami B, Nicoletti F, Buyon JP,
Meroni PL, Balestrieri G, Casali P: Human anticardiolipin mono-
clonal autoantibodies cause placental necrosis and fetal loss
in BALB/c mice.  Arthritis Rheum 1998, 41:1026-1039.
47. Di Simone N, Meroni PL, de Papa N, Raschi E, Caliandro D, De
Carolis CS, Khamashta MA, Atsumi T, Hughes GR, Balestrieri G,
et al.: Antiphospholipid antibodies affect trophoblast gonado-
tropin secretion and invasiveness by binding directly and
through adhered beta2-glycoprotein I.  Arthritis Rheum 2000,
43:140-150.
48. Inoue K, Nojima S: Immunochemical studies of phospholipids.
Reactivity of various synthetic cardiolipin derivatives with
Wasserman antibody.  Chem Phys Lipids 1967, 1:360-367.
49. Qamar T, Gharavi AE, Levy RA, Lockshin MD: Lysophosphati-
dylethanolamine is the antigen to which apparent antibody to
phosphatidylethanolamine binds.  J Clin Immunol 1990,
10:200-203.
50. Wu R, Huang YH, Elinder LS, Frostegard J: Lysophosphatidyl-
choline is involved in the antigenicity of oxidized LDL.  Arterio-
scler Thromb Vasc Biol 1998, 18:626-630.
51. Pruzanski W, Keystone EC, Sternby B, Bombardier C, Snow KM,
Vadas P: Serum phospholipase A2 correlates with disease
activity in rheumatoid arthritis.  J Rheumatol 1988,
15:1351-1355.